Joshua Z. Drago

Generating author description...

All published works

Action	Title	Year	Authors
+ PDF Chat	Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer	2020	Joshua Z. Drago Mithat Gönen Gita Thanarajasingam Chana A. Sacks Michael J. Morris Philip W. Kantoff Konrad H. Stopsack

Common Coauthors

Coauthor	Papers Together
Chana A. Sacks	1
Michael J. Morris	1
Mithat Gönen	1
Konrad H. Stopsack	1
Philip W. Kantoff	1
Gita Thanarajasingam	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials	2015	Gita Thanarajasingam Joleen M. Hubbard Jeff A. Sloan Axel Grothey	1
+	DEFINITION OF RATES: SOME REMARKS ON THEIR USE AND MISUSE	1975	Regina C. Elandt‐Johnson	1
+ PDF Chat	Randomized Trials Analyzed as Observational Studies	2013	Miguel A. Hernán Sonia Hernández–Dı́az James M. Robins	1
+ PDF Chat	Identifying and Addressing Safety Signals in Clinical Trials	2008	Thomas R. Fleming	1
+	Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement	2004	John P. A. Ioannidis	1
+ PDF Chat	New Paradigm in Dose-Finding Trials: Patient-Specific Dosing and Beyond Phase I	2005	André Rogatko James S. Babb Mourad Tighiouart Fadlo R. Khuri Gary R. Hudes	1
+	Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review	2013	Julien Péron Denis Maillet Hui Gan Eric X. Chen Benoît You	1
+ PDF Chat	Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer	2013	Francisco Vera-Badillo Roman M. Shapiro Alberto Ocaña Eitan Amir Ian F. Tannock	1
+ PDF Chat	Drug safety assessment in clinical trials: methodological challenges and opportunities	2012	Sonal Singh Yoon K. Loke	1
+ PDF Chat	Translation of Innovative Designs Into Phase I Trials	2007	André Rogatko David J. Schoeneck William Jonas Mourad Tighiouart Fadlo R. Khuri Alan L. Porter	1
+ PDF Chat	Adverse Event Reporting in Cancer Clinical Trial Publications	2013	Shanthi Sivendran Asma Latif Russell B. McBride Kristian Stensland Juan P. Wisnivesky Lindsay Haines William Oh Matthew D. Galsky	1
+	Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates	2008	Peter F. Thall Hoang Q. Nguyen Elihu H. Estey	1
+ PDF Chat	Quality of Reporting of Serious Adverse Drug Events to an Institutional Review Board: A Case Study with the Novel Cancer Agent, Imatinib Mesylate	2009	David A. Dorr Rachel E. Burdon Dennis P. West Jennifer Lagman Christina H. Georgopoulos Steven M. Belknap June M. McKoy Benjamin Djulbegović Beatrice J. Edwards Sigmund A. Weitzman	1
+	Approximate is Better than “Exact” for Interval Estimation of Binomial Proportions	1998	Alan Agresti Brent A. Coull	1
+ PDF Chat	Adverse Event Reporting in Publications Compared With Sponsor Database for Cancer Clinical Trials	2006	Orit Scharf A. Dimitrios Colevas	1
+	Statistical issues in the analysis of adverse events in time‐to‐event data	2016	Arthur Allignol Jan Beyersmann Claudia Schmoor	1
+ PDF Chat	Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254	2016	Gita Thanarajasingam Philip J. Atherton Paul J. Novotny Charles L. Loprinzi Jeff A. Sloan Axel Grothey	1
+	Per-Protocol Analyses of Pragmatic Trials	2017	Miguel A. Hernán James M. Robins	1
+	Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop	2017	Paul G. Kluetz Bindu Kanapuru Steven J. Lemery Laura Lee Johnson Mallorie H. Fiero Karen Arscott Yolanda Barbáchano Ethan Basch Michelle Campbell Joseph C. Cappelleri	1
+ PDF Chat	Validity and usefulness of a single‐item measure of patient‐reported bother from side effects of cancer therapy	2017	Timothy Pearman Jennifer L. Beaumont Daniel K. Mroczek M. O'Connor David Cella	1
+ PDF Chat	glmmTMB Balances Speed and Flexibility Among Packages for Zero-inflated Generalized Linear Mixed Modeling	2017	M. Brooks Kasper Kristensen Koen J. van Benthem Árni Magnússon Casper Willestofte Berg Anders Nielsen James S. Hans Martin Mächler M. Bolker Benjamin	1
+ PDF Chat	Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial	2019	Amylou C. Dueck Howard I. Scher Antonia V. Bennett Gina L. Mazza Gita Thanarajasingam Gisela Schwab Aaron Weitzman Lauren J. Rogak Ethan Basch	1
+	The Need for Combined Assessment of Multiple Outcomes in Noninferiority Trials in Oncology	2019	Ismail Jatoi Mitchell H. Gail	1